INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Foghorn Therapeutics
Back to Newsroom
🏢Organization Dossier

Foghorn Therapeutics

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

6 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech Just now (03:00 PM IST)

Foghorn Cuts 40% of Staff After Lilly Ends Cancer Pact on Data Concerns

Foghorn Therapeutics is laying off about 40% of its workforce after Eli Lilly terminated a cancer drug collaboration that had been a key strategic and financial pillar for the biotech company. The collapse of the partnership, reportedly tied to concerns over data quality, has intensified pressure on Foghorn’s pipeline and sent its shares sharply lower as investors reassess the company’s near-term prospects.

By RDU Global Wire5 min read
Startups & Venture CapitalJust now (02:02 PM IST)

Beam Therapeutics Sues Chinese Biotech and VC-Backed Startup Over Alleged IP Theft

Beam Therapeutics has filed suit against a Chinese biotech company and a venture-capital-backed startup, alleging theft of intellectual property tied to its gene-editing technology, according to STAT. The case adds to mounting tensions over biotech innovation, cross-border technology transfer, and the protection of proprietary research in a sector where patents and trade secrets are central to valuation.

6 min readRead →
Global Markets & Equities25 Oct 2026, 08:00 AM IST

Tango Reports 82% Tumor Response in Pancreatic Cancer Trial, Raising the Stakes in a Crowded Race

Tango Therapeutics said its combination therapy produced an 82% tumor response rate in an early-stage trial involving advanced pancreatic cancer, a result that could sharpen investor attention on one of oncology’s most difficult targets. The data add momentum to the company’s strategy, while also inviting scrutiny over durability, patient selection and whether the response can translate into a meaningful late-stage commercial opportunity.

5 min readRead →
Global Health & Biotech06 Oct 2026, 08:29 AM IST

AstraZeneca CEO Says Summit Drug Could Anchor Next Wave of Cancer Combinations After $2 Billion Bet

AstraZeneca Chief Executive Pascal Soriot said Summit Therapeutics’ cancer drug could become a foundation for the next generation of combination therapies, underscoring why the Anglo-Swedish drugmaker has committed about $2 billion to the biotech. The comments come as AstraZeneca and Daiichi Sankyo move to test Summit’s ivonescimab alongside Datroway, a sign that large pharmaceutical groups are racing to secure the most promising assets in oncology.

5 min readRead →
Clean Energy & Climate Transition04 Oct 2026, 08:22 AM IST

Poxvirus Study Reveals a Human Gene It Has Kept and Repurposed for Survival

Scientists have identified a poxvirus carrying a stolen human gene and, unusually, showing signs that it has retained and refined the genetic material over time rather than discarding it. The finding offers a rare window into how viruses can borrow from their hosts and adapt those genes for their own biology, with implications for virology, evolutionary research, and the design of future therapeutics.

5 min readRead →
Markets, IPOs & Wealth27 Oct 2026, 04:34 PM IST

Tech Is Pushing Healthcare Into a New Investment Cycle

From biosensors and wearables to 3D-printed skin, reconstructed organs and AI-enabled clinical trials, healthcare technology is moving beyond incremental innovation and into a structural shift. The change is reshaping how care is delivered, how drugs are tested and how investors assess the next wave of growth in health-related markets.

4 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Foghorn Therapeutics: